Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Virulent characteristics of multidrug resistant E. coli from Zaria, Nigeria

Global Experts Meeting on Infectious Diseases, Diabetes and Endocrinology

Igwe J C, Olayinka B O, Ehnimidu J O and Onaolapo J A

Gombe State University, NigeriaAhmadu Bello University, Nigeria

Posters & Accepted Abstracts: J Infect Dis Ther

DOI: 10.4172/2332-0877-C2-063

Abstract
Most Multi Drug Resistant (MDR) Escherichia coli isolates (resistant to more than 3 classes of antibiotics) exhibit co-virulent characteristics that contribute to mortality and morbidity as a result of resistance to commonly prescribed antibiotics in the clinics. This study evaluated phenotypically some virulent characteristics in E. coli that contribute to the expressed MDR properties of E. coli using standard microbiological methods. 87 E. coli isolates were confirmed as E. coli from urinary tract infection and diarrhea patients in selected hospitals in Zaria, Nigeria using Microgene identification kit, out of which 58.6% (51) were observed to be MDR. Significant number of the MDR isolates (70.6% (36)) were extended spectrum beta-lactamase producers, 45.1% (23) were resistant to Cefoxitin and produce ampC. While further analysis on the isolates showed that 23.5% (12) were biofilm producers, 47.1% (24) were hetero resistant to Cefoxitin while 5.9% (3) produced carbapenemase. This study showed that most MDR E. coli from UTI and diarrhea could exhibit more than one virulent characteristic. Hence, isolates with MDR should be subjected to various tests in other to validate the mechanisms of resistance. This will encourage better treatment options and good periodic surveillance in prescription and dispensing of antibiotics in clinical settings.
Biography

E-mail: Igwejames42@yahoo.com

 

Top